Dynamic Follow-up of Symptoms Based on Patient-reported Outcomes in Immunotherapy for Esophageal Cancer: a Prospective Multicentre Cohort Study (SPRING)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

220 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-10

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Immunotherapy shows satisfactory effectiveness and safety in patients with esophageal cancer. Immunotherapy-based regimens have a better survival benefit compared to previous chemotherapy and radiotherapy. Patient-reported outcomes (PRO) provide a reliable assessment of patients' functional status during treatment. However, the spectrum of symptoms in esophageal cancer patients receiving immunotherapy is uncertain, and there are no studies applying the symptom bank based on PRO to the immunotherapy model for esophageal cancer. In this prospective study, the investigators aimed to preliminarily screen for symptoms associated with immunotherapy for esophageal cancer through a systematic literature review and expert evaluation, and build a symptom item bank for esophageal cancer patients receiving immunotherapy. Adverse symptoms in esophageal cancer patients treated with immunotherapy were collected prospectively. The distribution and severity of the symptoms, as well as the trajectory of symptom change were further analyzed to demonstrate the validity and reliability of the symptom item bank. It would refine the spectrum of symptoms for esophageal cancer patients receiving immunotherapy and provide a foundation for assessing the specific symptom burden in patients with esophageal cancer receiving immunotherapy regimens.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Real-World Study of Immune Checkpoint Inhibitors and Chemotherapy for Advanced Esophageal Cancer

NCT04822103

Esophageal Cancer

COMPLETED

Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting

NCT05615129

Esophagus Cancer

COMPLETED

A Study of the Tumor Microenvironment Affecting the Efficacy of Immunotherapy for Esophageal Cancer

NCT06219031

Esophageal Cancer

COMPLETED

The PET-CT Predicting Response to Immunochemotherapy in Esophageal Cancer

NCT05615103

Esophageal Cancer

UNKNOWN

Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma

NCT05894369

Esophageal Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Cancer Patient-reported Outcomes Immunotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Monoimmunotherapy group

No interventions assigned to this group

Chemoimmunotherapy group

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pathologically confirmed resectable, locally advanced, advanced metastatic esophageal cancer
* Having received or undergoing an immunotherapy-based treatment regimen
* Age 18-75 years
* ECOG PS of 0-2
* Adequate organ function
* Life expectancy \> 6 months
* Participants are fully informed about the whole study and are willing to sign the informed consent

Exclusion Criteria

* Absence of immunotherapy regimen, or recieving radiotherapy.
* Presence of primary tumours elsewhere, such as gastric cancer, lung cancer or cervical cancer
* Severe organ function deterioration and intolerance to immunotherapy
* Pregnant or breast-feeding women
* Previous autoimmune disease
* Any other conditions that may affect patients' safety and compliance
* Psychological, family, social and other factors leading to inability to inform consent

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No